0000950170-24-009397.txt : 20240131 0000950170-24-009397.hdr.sgml : 20240131 20240131161513 ACCESSION NUMBER: 0000950170-24-009397 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240130 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 24583079 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 abio-20240130.htm 8-K 8-K
0000907654false00009076542024-01-302024-01-30

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 31, 2024 (January 30, 2024)

 

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10170 Church Ranch Way

Suite 100

 

Westminster, Colorado

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

ABIO

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

 

On January 30, 2024, the Board of Directors (the “Board”) of ARCA biopharma, Inc. (the “Company”) approved paying compensation to its existing non-employee directors, pursuant to the Company’s Director Compensation Policy, by granting each of Drs. Linda Grais, Anders Hove and Raymond Woosley, and Messrs. Robert Conway, Daniel Mitchell, Jacob Ma-Weaver and James Flynn options to purchase 6,000 shares of the Company's common stock (the "Options") at an exercise price of $1.64 per share, the closing price of the Company’s common stock on The Nasdaq Global Market on January 30, 2024, rounded up to the nearest whole cent. The Options are subject to the terms and conditions of the ARCA 2020 Equity Incentive Plan (the "Plan") and the Company’s standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The Options vest in 12 equal monthly installments beginning on January 30, 2024, assuming Drs. Grais’, Hove's and Woosley's, and Messrs. Conway’s, Mitchell’s, Ma-Weaver's and Flynn's continued service on the Board for such periods.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On January 30, 2024, the Company held the 2023 Annual Meeting of Stockholders at which the Company’s stockholders voted upon (i) the election of Company nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board for a three-year term ending at the 2026 Annual Meeting of Stockholders, (ii) the ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 and (iii) the approval, on an advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company's Proxy Statement filed with the Securities and Exchange Commission on December 19, 2023.

The stockholders elected the director nominees, ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, and approved the resolution concerning the advisory vote on the compensation of the Company’s named executive officers. The tabulation of votes cast with respect to each matter voted upon, as applicable, was as follows:

1. Election of Directors:

 

 

 

 

 

 

 

Nominee

For

Withheld

Broker Non-Votes

Dr. Michael R. Bristow

6,952,545

1,088,323

2,577,852

Mr. Robert E. Conway

6,758,409

1,282,459

2,577,852

 

2. Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023:

 

 

 

 

 

 

 

For

Against

Abstentions

Broker Non-Votes

10,286,650

263,929

68,141

—

 

3. Executive Compensation:

 

 

 

 

 

 

 

For

Against

Abstentions

Broker Non-Votes

6,548,473

1,472,454

19,941

2,577,852

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

Exhibit Number

 

Description

 

 

104

Cover Page Interactive Data File (embedded within the inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCA biopharma, Inc.
(Registrant)

 

 

 

 

Date:

January 31, 2024

By:

/s/ C. Jeffrey Dekker

 

 

 

Name: C. Jeffrey Dekker
Title: Chief Financial Officer

 

 EX-101.SCH 2 abio-20240130.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 3 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
Jan. 30, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 30, 2024
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity Emerging Growth Company false
Entity File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code (720)
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports abio-20240130.htm abio-20240130.xsd http://xbrl.sec.gov/dei/2023 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abio-20240130.htm": { "nsprefix": "abio", "nsuri": "http://www.arcabiopharma.com/20240130", "dts": { "inline": { "local": [ "abio-20240130.htm" ] }, "schema": { "local": [ "abio-20240130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_148660f2-bd82-4e83-8139-c176c727d865", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20240130.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_148660f2-bd82-4e83-8139-c176c727d865", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20240130.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.arcabiopharma.com/20240130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 12 0000950170-24-009397-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-009397-xbrl.zip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abio-20240130_htm.xml IDEA: XBRL DOCUMENT 0000907654 2024-01-30 2024-01-30 0000907654 false 8-K 2024-01-30 ARCA biopharma, Inc. DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 (720) 940-2200 false false false false Common ABIO NASDAQ false